Form 8-K - Current report:
SEC Accession No. 0001140361-25-024089
Filing Date
2025-06-30
Accepted
2025-06-30 07:37:57
Documents
13
Period of Report
2025-06-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20051351_8k.htm   iXBRL 8-K 46078
2 EXHIBIT 2.1 ef20051351_ex2-1.htm EX-2.1 1974132
  Complete submission text file 0001140361-25-024089.txt   2533420

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA bcrx-20250627.xsd EX-101.SCH 3865
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE bcrx-20250627_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bcrx-20250627_pre.xml EX-101.PRE 16044
15 EXTRACTED XBRL INSTANCE DOCUMENT ef20051351_8k_htm.xml XML 4205
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-23186 | Film No.: 251088764
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)